BaseSpace
Correlation
Engine-Public
Sign In
Register
Correlation Engine 2.0
Home
My Data
Bookmarks
Collaborations
Inbox
Import Your Data
QuickView
FAQ
What is QuickView?
What can my QuickView results tell me?
What are the sources for the General Info tab in QuickView?
More QuickView FAQs
Back to top
QuickView
Curated
Studies
Body
Atlas
Disease
Atlas
Pharmaco
Atlas
Knockdown
Atlas
Genetic
Markers
Pathway
Enrichment
Literature
Clinical
Trials
0
Meta-
Analysis
QuickView
Search sequence regions
(e.g.
Fenofibrate
,
rs2230926
,
PPARA
,
cell-cell adhesion
,
Breast Cancer
,
Endothelial cell
)
Organisms
Chromosomes
Start
Stop
Homo Sapiens
Mus Musculus
Rattus Norvegicus
C. Elegans
D. Melanogaster
Saccharomyces Cerevisiae
QuickView
Go back to main search
Bookmark
Forward
QuickView
for
FAM83A
(gene)
Summary
General Info
Body Atlas
Most Correlated Tissues
Pharyngeal mucosa
Vulva
Vagina
Penis
Cervix
Explore Body Atlas Results
Disease Atlas
Most Correlated Diseases
Loading...
Explore Disease Atlas Results
Pharmaco Atlas
Most Correlated Compounds
Loading...
Explore Pharmaco Atlas Results
Knockdown Atlas
Most Correlated Gene Perturbations
Loading...
Explore Knockdown Atlas Results
Curated Studies
Most Correlated Studies
Cervical cancer tissues with high-risk HPV infection from patients
Explore Curated Studies Results
Literature
Most Relevant Literature
Sense and anti-sense: Role of FAM83A and FAM83A-AS1 in Wnt, EGFR, PI3K, EMT pathways and tumor progr…
LncRNA FAM83A-AS1 promotes epithelial-mesenchymal transition of pancreatic cancer cells via Hippo pa…
ncRNA-mediated upregulation of FAM83A is associated with poor prognosis and immune infiltration in p…
LncRNA FAM83A-AS1 promotes lung adenocarcinoma progression by enhancing the pre-mRNA stability of FA…
High-risk histological subtype-related FAM83A hijacked FOXM1 transcriptional regulation to promote m…
Explore Literature Results
Clinical Trials
Most Relevant Clinical Trials
There were no clinical trials for FAM83A
Explore Clinical Trials Results
search
→
result
search
→
result
See more about this page
See complete FAQ